Éthosuximide,

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Ethosuximide has been used:to confirm its effect on spike wave discharges (SWD) in ratsto examine its effects on spontaneous locomotion and anxiety-related thigmotaxis behaviours in zebrafish larvae of wild typeas a model drug for the treatment of epilepsy in vivo(4)

Biochem/physiol Actions

Ethosuximide is an anticonvulsant drug and an antagonist for T-type calcium channel. It is known to prevent spike wave discharges, characterized in absence seizures.

Features and Benefits

This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Other Notes

Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. E7138.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

Packaging

5, 100 g in glass bottle